Grünenthal formulates deal with Patheon for anti-abuse technology

By Dan Stanton

- Last updated on GMT

Image: iStock/Elrepho385
Image: iStock/Elrepho385

Related tags Drug Pharmacology Opioid

Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.

The agreement will see the contract development and manufacturing organisation (CDMO) help advance Grünenthal’s abuse-deterrent formulation technology platform, INTAC, for the German pharma firm’s opioid pipeline.

The technology platform itself is based on the Hot Melt Extrusion (HME) process, explained Grünenthal spokesperson Steffen Fritzsche.

“HME is an innovative and viable technique that has been effectively utilised in the pharmaceutical industry,“​ he told “With that technology we are able to provide tailored formulations for extended release, immediate release and modified drug release additionally providing our established abuse deterrent properties.“

When applied to opioid drugs, the platform can help tackle the growing problem of abuse in the US, something that is falling more and more onto the shoulders of drugmakers, he continued.

“Technologies with proven track record have a clear advantage in this competitive environment. This is favourable for Grünenthal since our company has been a pioneer and is today an acknowledged expert in the field of abuse deterrent formulations.“

Preferred CDMO

Financial terms of the deal were not revealed but Patheon, acting as a strategic partner, says production work will be conducted under its “condo model,”​ a service for clients which helps to simplify manufacturing by bringing equipment and technologies into the CDMO’s own facilities.

“This agreement is a tangible example of the deeper, collaborative relationships we are pursuing and winning with clients,”​ said Mike Lehmann, EVP at Patheon.

And therefore, Fritzsche told us: “A full set of equipment required for development and manufacturing activities with Grünenthal’s proprietary technology will be installed at Patheon’s Cincinnati manufacturing site.Contracts are set-up to ensure that IP rights of involved parties are fully considered.“

The decision to select Patheon was driven in part by Grünenthal‘s established development relationship with the CDMO, he added.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Access GMP process liquids

Access GMP process liquids

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Apr-2023 | Product Brochure

Accelerate your development and manufacturing of life-changing medicines with a reliable supply of your critical GMP-manufactured process liquids. Gibco...

Related suppliers

Follow us


View more